01 / CLASS
2'-sugar modification
2'-fluoro and 2'-O-methyl substitutions raise duplex stability, block nucleases and reduce immunostimulation while preserving RNAi activity.
2'-OMe2'-FDuplex stabilityImmune evasion
Gene Therapy / Resources /
siRNA Modification Selection Guide
Gene Therapy Resource
siRNA Modification Selection Guide
Small interfering RNA potency is only partly a matter of sequence. Sugar, backbone and terminal modifications determine nuclease resistance, guide-strand selectivity, off-target silencing and immune activation. A common design combines 2′-fluoro and 2′-O-methyl modifications across the duplex, places additional 2′-O-methyl groups in the seed region to reduce miRNA-like off-target effects, and uses limited terminal phosphorothioate linkages to improve stability. Delivery requirements then determine whether GalNAc, antibody, peptide, or another conjugate is appropriate, with the least chemically complex pattern that meets potency, specificity, tolerability, and tissue-exposure requirements generally preferred.
01 Nuclease resistance 2'-modifications protect the duplex.
02 Strand selectivity Seed and 5'-end chemistry favor the guide strand.
03 Off-target control Seed-region tuning reduces unintended silencing.
04 Immune evasion Chemistry dampens innate RNA sensing.
Direct Answer
Which siRNA modifications should be combined?
Therapeutic siRNAs almost always pair a 2'-modification pattern with a limited phosphorothioate (PS) backbone. 2'-fluoro and 2'-O-methyl substitutions provide nuclease resistance and blunt innate immune recognition, while a small number of PS linkages stabilize the strand ends and support conjugation. The exact placement matters: modifying the guide-strand seed region can suppress off-target silencing, and leaving the 5'-end phosphate or chemistry compatible with RISC loading preserves on-target activity.
The decision rule: start from the delivery route and the potency-versus-safety balance, then layer sugar, backbone and terminal chemistry to reach the required stability and specificity. Creative Biolabs supports this through custom siRNA synthesis and custom oligonucleotide modification so chemistry and sequence are evaluated together.
02 / CLASS
Backbone modification
Phosphorothioate linkages, usually limited to the strand termini, resist exonuclease degradation and aid protein binding and delivery without globally impairing potency.
End stabilizationNuclease resistanceConjugate attachment
03 / CLASS
Nucleobase modification
Base changes such as 5-methyl-cytidine reduce immunostimulatory motifs and can fine-tune duplex stability without altering the coding sequence.
ImmunostimulationDuplex tuningBase-pairing control
04 / CLASS
Terminal and linker chemistry
Conjugates such as GalNAc direct hepatocyte uptake, while fluorophore, biotin, amino and thiol handles add detection, purification and surface-attachment capability.
GalNAc targetingFluorophore labelingBiotin captureThiol conjugation
Sugar Chemistry
The 2'-modification pattern drives specificity
Where a modification sits is as important as which modification is used. Seed-region and strand-end chemistry determine how cleanly the guide strand silences its intended target.
2'-O-methyl
Increases nuclease resistance and duplex stability while reducing off-target activity when placed in the guide-strand seed region. DNA/2'-O-methyl RNA chimeras apply the same chemistry in mixed backbone designs.
2'-fluoro
Further raises stability and affinity while dampening innate immune recognition of the double-stranded RNA, a key requirement for systemic delivery.
Pattern and placement
A common design alternates 2'-F and 2'-OMe across both strands, then refines the seed region of the guide strand to reduce seed-mediated off-target effects while preserving the 5'-end requirements for RISC loading.
Backbone by Design
Phosphorothioate is used sparingly but strategically
Unlike ASOs, siRNAs do not require a fully substituted phosphorothioate backbone. Too many PS linkages can lower potency and increase nonspecific protein binding, so they are concentrated where they deliver the most value.
Terminal stabilization
PS linkages at the 5' and 3' ends protect against exonuclease degradation, extending the intact duplex lifetime in serum and cells.
Conjugation anchor
A terminal PS or linker provides the attachment point for GalNAc and other delivery moieties without disturbing the double-stranded core.
Potency balance
Excess PS substitution can reduce silencing activity and increase nonspecific interactions, so density is kept low relative to gapmer ASOs. Phosphorothioate placement is therefore tuned case by case.
Delivery and Labeling Chemistry
Terminal chemistry turns an siRNA into a deliverable drug
The terminal position is where delivery and detection functions are attached, so it links the stability chemistry inside the duplex to the targeting strategy outside it.
GalNAc targeting
A triantennary GalNAc ligand attached at the sense strand directs hepatocyte uptake through the asialoglycoprotein receptor. N-Acetylgalactosamine (GalNAc) is the standard route for liver-directed RNAi.
Antibody and peptide conjugation
Linkers attached through terminal chemistry enable antibody-siRNA conjugates and cell-penetrating designs that extend delivery beyond the liver.
Detection labels
Fluorophores support imaging and biodistribution studies, while quenchers enable FRET-based activity assays.
Purification handles
Biotin, amino and thiol modifiers add capture or surface-conjugation capability for enrichment and assay development.
Selection Guide
Select modifications against the delivery route and safety target
The intended route of administration and the required specificity define the modification pattern more than the target sequence itself.
| Program goal | Recommended modification pattern | Reasoning |
|---|---|---|
| Systemic, liver-targeted silencing | 2'-F/2'-OMe duplex, terminal PS, GalNAc conjugate | Sugar chemistry confers stability and immune evasion; GalNAc directs hepatocyte uptake for subcutaneous dosing. |
| Maximal on-target specificity | 2'-OMe in the guide seed region | Seed modifications suppress miRNA-like off-target silencing without losing guide-strand activity. |
| Reduced innate immune activation | 2'-F plus 2'-OMe, 5-methyl-cytidine | Sugar and nucleobase changes blunt TLR-mediated sensing of double-stranded RNA. |
| In vitro screening and QC | Minimal PS, optional fluorophore or biotin label | Keeps synthesis simple while adding detection or capture handles for assays. |
| Extrahepatic delivery | Terminal linker for antibody or peptide conjugate | A conjugation-ready terminus supports receptor-mediated or cell-penetrating targeting. |
Start from delivery
Confirm the administration route and tissue, since conjugate chemistry depends on the targeting strategy.
Layer for stability
Add 2'-sugar and terminal PS chemistry to reach the required serum and cellular half-life.
Tune for specificity
Refine the seed region to balance on-target potency against off-target silencing.
Project Support
Creative Biolabs Support
Creative Biolabs builds modified siRNAs from sequence through conjugate, so chemistry, delivery and activity are evaluated as a single candidate rather than separate steps.
| Research Need | Related Creative Biolabs Support | How It Connects to the Current Topic |
|---|---|---|
| Add a specific chemical modification | Custom Oligonucleotide Modification Service | Applies sugar, backbone, nucleobase and terminal modifications to a candidate duplex. |
| Synthesize the modified siRNA | Custom siRNA Synthesis | Produces the chosen 2'-F/2'-OMe and PS pattern at the required scale and purity. |
| Add a GalNAc or delivery conjugate | N-Acetylgalactosamine (GalNAc) | Attaches the hepatocyte-targeting ligand that enables subcutaneous, liver-directed dosing. |
| Verify knockdown activity | siRNA In Vitro Screening Service | Provides functional readouts to compare modification variants before scale-up. |
| Track clinical-stage siRNA chemistry | siRNA-based Therapeutics in Clinical Trials | Contextualizes modification choices against the chemistry used in advanced programs. |
| Explore conjugation options | Antibody-siRNA Conjugates (ARCs) | Extends delivery beyond the liver when a conjugate terminus is required. |
Selected Literature
Evidence behind siRNA modification choices
siRNA Chemistry
Chemical modification of siRNAs for therapeutic use
A review of the sugar, backbone and terminal chemistry used to stabilize siRNAs and reduce off-target effects.
Off-Target Control
Seed-region modification and siRNA off-target silencing
Evidence that 2'-O-methyl placement in the guide-strand seed region suppresses miRNA-like off-target effects.
Delivery Chemistry
GalNAc conjugation for liver-directed RNAi
Description of asialoglycoprotein-receptor targeting as the basis for subcutaneous siRNA delivery to hepatocytes.
FAQ
siRNA modification FAQs
The answers below describe modification selection at a general level.
Design an siRNA modification pattern around your target and delivery need
Share your target sequence, delivery route, tissue and specificity requirements. Creative Biolabs can help scope the sugar, backbone, nucleobase and terminal chemistry to build a stable, specific and deliverable candidate.
Contact Creative BiolabsStart Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
